Free Trial

CVRx Q3 2023 Earnings Report

CVRx logo
$11.56 +0.26 (+2.30%)
As of 03/11/2025 04:00 PM Eastern

CVRx EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

CVRx Revenue Results

Actual Revenue
$10.51 million
Expected Revenue
$9.83 million
Beat/Miss
Beat by +$680.00 thousand
YoY Revenue Growth
N/A

CVRx Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

CVRx Earnings Headlines

Your Wealth is Under Attack
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
CVRx Full Year 2024 Earnings: EPS Misses Expectations
See More CVRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CVRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CVRx and other key companies, straight to your email.

About CVRx

CVRx (NASDAQ:CVRX), a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

View CVRx Profile

More Earnings Resources from MarketBeat